UNICORN trial: Fc-enhanced anti-CTLA-4 botensilimab in neoadjuvant colon cancer — dMMR combination MPR 100% (14/14)
Short-course preoperative Fc-enhanced anti-CTLA-4 botensilimab, alone or combined with anti-PD-1 balstilimab, was evaluated in resectable locally advanced pMMR or dMMR colon cancer. Major pathological response (MPR) rates were 0% (0/14) and 36% (5/14) in the pMMR monotherapy and combination cohorts and 36% (5/14) and 100% (14/14) in the corresponding dMMR cohorts; pCR was 93% (13/14) in the dMMR combination cohort. ctDNA clearance correlated with pathological response.

Background and open questions
Checkpoint inhibitors have transformed treatment of microsatellite-unstable (dMMR) colorectal cancer, but microsatellite-stable (pMMR) tumors—which represent 85% of cases—remain largely resistant. Fc-enhanced anti-CTLA-4 antibodies like botensilimab are designed to more potently deplete regulatory T cells and enhance antitumor immunity. Whether this mechanism could unlock responses in pMMR colon cancer was a key question.
Study design
The UNICORN trial was a nonrandomized phase 2 window-of-opportunity study enrolling 56 patients with resectable locally advanced colon cancer across four sequentially allocated cohorts of 14 patients each: pMMR receiving botensilimab alone, pMMR receiving the combination with balstilimab, dMMR receiving botensilimab alone, and dMMR receiving the combination. The primary endpoint was major pathological response (MPR).
Key results
- In pMMR patients, MPR was 0% (0/14) with botensilimab monotherapy and 36% (5/14) with the combination; pCR was 0% and 29% (4/14), respectively.
- In dMMR patients, MPR was 36% (5/14) with monotherapy and 100% (14/14) with the combination; pCR was 29% (4/14) and 93% (13/14), respectively.
- All but the pMMR monotherapy cohort met the primary endpoint.
- Immune-related adverse events occurred in 8/28 (29%) with botensilimab alone and 15/28 (54%) with the combination, mostly flu-like symptoms and diarrhea; no adverse-event-related deaths.
- ctDNA clearance correlated with pathological response.
Mechanistic interpretation
The Fc-enhanced design of botensilimab may provide stronger Treg depletion and immune activation than conventional anti-CTLA-4 antibodies. The combination with PD-1 blockade appears necessary to generate responses in the historically resistant pMMR population, though the effect is still modest compared with dMMR tumors.
Limitations
- The study uses small sequential cohorts and is not a randomized treatment comparison.
- The pMMR combination response (36% MPR) is encouraging but remains lower than the dMMR combination (100%).
- Long-term outcomes such as recurrence-free and overall survival are not yet available.
Authors and source
Nature Medicine (2026). Published online 2 November 2026. https://doi.org/10.1038/s41591-026-04710-1.
Numbers are as reported by the authors. Corrections: contact@
Related science
Regulatable IL-15 engineered TIL therapy in checkpoint-inhibitor-resistant melanoma: 67% ORR at the RP2D
OBX-115 expresses acetazolamide-regulatable membrane-bound IL-15, removing the need for exogenous IL-2
Anti-GDF-15 visugromab plus nivolumab before surgery in bladder cancer: pCR 33% vs 8%
In the phase 2a GDFATHER-NEO trial, adding GDF-15 neutralisation to nivolumab raised pathologic responses without adding grade 3–4 toxicity
Intratumoural anti-CTLA4 + anti-PD1: 24.3% grade 3–4 toxicity at 6 months
Intratumoural antibody injection, antibody delivered through a vessel, T cells infiltrating the tumour
One email, with links to every paper. Reports and custom landscapes: contact@inlightbio.com.
Opens your email app with a pre-filled request; we add you by hand. Free, unsubscribe any time.


